Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders

Clinical Lymphoma and Myeloma

Volumn 7, Issue 7, 2007, Pages 462-466

  Auwerda, Johannes J A ^a,b   Sonneveld, Pieter ^a   De Maat, Moniek P M ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

Author keywords

Monoclonal gammopathy of uncertain significance; Systemic amyloidosis; Waldenstr m's macroglobulinemia

Indexed keywords

ANTHRACYCLINE; BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADULT; AMYLOIDOSIS; ARTICLE; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; RISK ASSESSMENT; THROMBOSIS; WALDENSTROEM MACROGLOBULINEMIA;

EID: 34548753399     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.027     Document Type: Article

References (25)

1. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021-1030.
2. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-831.
3. Stkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558-566.
4. Sallah S, Husain A, Wan J, et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15:1490-1494.
5. Srkalovic G, Cameron MG, Deitcher SR, et al. Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis. Int Semin Surg Oncol 2005; 2:17.
6. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13:187-192.
7. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17:237-246.
8. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
9. Wolf M, Boyer-Neumann C, Leroy-Matheron C, et al. Functional assay of protein S in 70 patients with congenital and acquired disorders. Blood Coagul Fibrinolysis 1991; 2:705-712.
10. Gomez E, van der Poel SC, Jansen JH, et al. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood 1998; 91:2208-2209.
11. Auwerda JJ, Sonneveld P, de Maat MP, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92:279-280.
12. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-3116.
13. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8:2210-2216.
14. Rajkumar SV, Hayman S, Greipp PR. Angiogenesis in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:262-264.
15. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742.
16. Stirling D, Hannanr WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998; 79:74-78.
17. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammarory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100-106.
18. Zezos P, Papaioannou G, Nikolaidis N, et al. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11:7639-7645.
19. Sawyerr AM, Smith MS, Hall A, et al. Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases. Dig Dis Sci 1995; 40:793-799.
20. Apetrei E, Ciobanu-Jurcut R, Rugina M, et al. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation. Rom J Intern Med 2004; 42:95-102.
21. Nijziel MR, van Oerle R, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120:117-122.
22. Hugo JZ, Jeanet DM. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 4:11.
23. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134:399-405.
24. Uptichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16:97-110.
25. Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006; 47:947-955.